Metaclipse Therapeutics
Business Services · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3175 Presidential Dr, Atlanta, Georgia, ...Phone Number
(404) 380-1342Website
www.metaclipse.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Metaclipse Therapeutics
Metaclipse Therapeutics specializes in developing innovative immunotherapies and vaccines, focusing on personalized treatments for cancer and infectious diseases. Their lead product, Membrex, is an autologous immunotherapy platform designed to stimulate immune responses against various advanced cancers, with clinical trials expected to begin in 2025. Additionally, the VaxRex vaccine platform aims to provide robust protection against infectious diseases, particularly for vulnerable populations. The company plans to commercialize its products through licensing agreements with major pharmaceutical firms after establishing their safety and effectiveness.Explore more
Metaclipse Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Metaclipse Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Metaclipse Therapeutics recently announced quarterly report
Product Launch: Get notified when Metaclipse Therapeutics launches new products
Check out if Metaclipse Therapeutics is spiking on competitors!
Metaclipse Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Metaclipse Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Metaclipse Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check if Metaclipse Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Metaclipse Therapeutics
Recommended Actions
Reach out to Masked Content who joined Metaclipse Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Metaclipse Therapeutics
Compare insights from companies similar to Metaclipse Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Metaclipse Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Metaclipse Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Metaclipse Therapeutics.
Metaclipse Therapeutics financials insights
Gather financial insights about Metaclipse Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Grant
$100K
2016
Grant
$2.4M
2021
Debt
$85K
Metaclipse Therapeutics Tech Stack
A closer look at the technologies used by Metaclipse Therapeutics
Metaclipse Therapeutics News & Media
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Metaclipse Therapeutics
Sign Up For FreeTo access detailed company insights
Metaclipse Therapeutics specializes in developing innovative immunotherapies and vaccines, focusing on personalized treatments for cancer and infectious diseases. Their lead product, Membrex, is an autologous immunotherapy platform designed to stimulate immune responses against various advanced cancers, with clinical trials expected to begin in 202... Read More
